BMS 193885 is a selective and competitive neuropeptide Y(1) receptor antagonist with affinity of 3.3 nM.

BMS 193885 increases the Kd of [(125)I]PeptideYY from 0.35 nM to 0.65 nM without changing the Bmax (0.16 pmol/mg of protein) in SK-N-MC cells that endogenously express the neuropeptide Y(1) receptor[1]. BMS 193885 is a full antagonist with an apparent Kb of 4.5 nM measured by reversal of forskolin-stimulated inhibition of cAMP production by neuropeptide Y[1].

BMS 193885 (10 mg/kg; i.p.) reduces one-hour neuropeptide Y-induced food intake in satiated rats, as well as spontaneous overnight food consumption. Chronic administration of BMS 193885 (10 mg/kg) i.p. for 44 days significantly reduces food intake and the rate of body weight gain compared to vehicle treated control without developing tolerance or affecting water intake[1].